Seroatlas · Human Serome Atlas

LILRA2

Leukocyte immunoglobulin-like receptor subfamily A member 2

Also known as: CD85h, ILT1, LIR-7, LIR7, LIRA2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q8N149
Gene
LILRA2
Ensembl
ENSG00000239998
Chromosome
19
Canonical length
483 aa
Protein class
CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins
Secretome location
Secreted to blood
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene encodes a member of a family of immunoreceptors that are expressed predominantly on monocytes and B cells, and at lower levels on dendritic cells and natural killer cells. The encoded protein is an activating receptor that inhibits dendritic cell differentiation and antigen presentation and suppresses innate immune response. Alternatively spliced transcript variants encoding different isoforms have been found. This gene is located in a cluster of related genes on chromosome 19 and there is a pseudogene for this gene on chromosome 3. [provided by RefSeq, Mar 2014]

Canonical amino-acid sequenceUniProt

483 residues, UniProt reviewed canonical sequence.

>Q8N149|LILRA2
     1  MTPILTVLIC LGLSLGPRTH VQAGHLPKPT LWAEPGSVII QGSPVTLRCQ GSLQAEEYHL
    61  YRENKSASWV RRIQEPGKNG QFPIPSITWE HAGRYHCQYY SHNHSSEYSD PLELVVTGAY
   121  SKPTLSALPS PVVTSGGNVT LQCVSQVAFD GFILCKEGED EHPQRLNSHS HARGWSWAIF
   181  SVGPVSPSRR WSYRCYAYDS NSPYVWSLPS DLLELLVPGV SKKPSLSVQP GPMVAPGESL
   241  TLQCVSDVGY DRFVLYKEGE RDFLQRPGWQ PQAGLSQANF TLGPVSPSHG GQYRCYSAHN
   301  LSSEWSAPSD PLDILITGQF YDRPSLSVQP VPTVAPGKNV TLLCQSRGQF HTFLLTKEGA
   361  GHPPLHLRSE HQAQQNQAEF RMGPVTSAHV GTYRCYSSLS SNPYLLSLPS DPLELVVSEA
   421  AETLSPSQNK TDSTTTSLGQ HPQDYTVENL IRMGVAGLVL VVLGILLFEA QHSQRSLQDA
   481  AGR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LILRA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.35
Highest tissue expression
57 nTPM

Expression across tissuesHPA

Tissue

  • spleen: 57 nTPM
  • bone marrow: 15 nTPM
  • lung: 10 nTPM
  • spinal cord: 6.3 nTPM
  • adipose tissue: 5 nTPM
  • midbrain: 4.5 nTPM

Single-cell type

  • neutrophils: 40 nCPM
  • microglia: 35 nCPM
  • monocytes: 17 nCPM
  • monocyte progenitors: 11 nCPM
  • kupffer cells: 9.2 nCPM
  • macrophages: 7.2 nCPM

Immune cell

  • neutrophil: 32 nTPM
  • intermediate monocyte: 12 nTPM
  • non-classical monocyte: 11 nTPM
  • classical monocyte: 7.7 nTPM
  • total PBMC: 6.1 nTPM
  • basophil: 5.1 nTPM

Brain region

  • medulla oblongata: 4.5 nTPM
  • white matter: 4.2 nTPM
  • pons: 4 nTPM
  • thalamus: 3.5 nTPM
  • midbrain: 3 nTPM
  • spinal cord: 2.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.75
gnomAD pLI
0
gnomAD missense Z
-2.7
DepMap mean gene effect
0.16
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LILRA2 as an antibody target. Whether an autoantibody or antibody against LILRA2 could matter depends on whether native LILRA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LILRA2 is annotated at the cell surface, where native LILRA2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LILRA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LILRA2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...